Hereditary Cancer Syndromes

APC I1307K Mutation

What You Should Know About the Low/Moderate Penetrance APC Variant I1307K (c.3920T>A)

Most pathogenic/likely pathogenic (P/LP) variants in the APC gene are associated with a severe genetic condition known as familial adenomatous polyposis syndrome or FAP. Individuals with FAP develop 100s to 1,000s of colon polyps in their lifetime and have almost a 100% risk of developing colon cancer without intervention. However, the I1307K APC variant (c.3920T>A) does not cause FAP. This variant is found in approximately 6-7% of the Ashkenazi Jewish population in the United States and moderately increases the risk of colorectal cancer.

UTSW’s hereditary cancer program is one of the largest in the nation, and we have extensive experience supporting individuals with the I1307K APC variant.

Cancer Risks Associated with the I1307K APC Variant

The risk for colorectal cancer in individuals with the I1307K APC variant is 5-10%. This is compared to the general population’s lifetime risk of 4.1% for developing colorectal cancer.

Managing Cancer Risks

Individuals with the I1307K APC variant should talk to their health care team about an appropriate cancer surveillance plan.

Colon Cancer

Our specialists follow recommendations from the National Comprehensive Cancer Network (NCCN), including:
- Colonoscopy every five years starting at age 40
- Possibly modifying the frequency or starting age if there is colon cancer in the family

Risks to Family Members

The I1307K APC variant is inherited in an autosomal dominant fashion. This means that children, brothers, sisters, and parents of individuals with this variant have a 1 in 2 (or 50%) chance of having the variant as well. Both males and females can inherit the variant, and both males and females can pass it on to their children.

ATM-Associated Cancers

Individuals with a pathogenic/likely pathogenic (P/LP) variant in the ATM gene have an increased risk for cancers of the breast, ovary, pancreas, and colon. Females have up to a 25% lifetime risk for breast cancer and up to a 5% lifetime risk for ovarian cancer. Males and females with the variant have up to a 10% risk for pancreatic cancer and a 10% risk for colorectal cancer.

AXIN2-Associated Cancers

What You Should Know About AXIN2 Pathogenic/Likely Pathogenic Variants

Individuals with a pathogenic/likely pathogenic (P/LP) variant in the AXIN2 gene have an increased risk for colon cancer.

UTSW is home to one of the largest hereditary cancer programs in the country, with specialized expertise in the clinical management of patients carrying P/LP variants of the AXIN2 gene.

Cancer Risks Associated with an AXIN2 P/LP Variant

Individuals with an AXIN2 P/LP variant have an increased risk of colon adenomas, polyps, and colon cancer. The lifetime risk for colon cancer is unknown. Individuals with the variant may also have permanent teeth that are missing (oligodontia) and sparse eyebrows, scalp, and body hair.

Managing Cancer Risks

UT Southwestern’s Genetic Cancer Prevention Clinic (GCPC) can help ensure people are receiving appropriate cancer surveillance and management based on their genetic testing results. For more information about the GCPC or to request an appointment, please call us at 214-645-2563.

Colon Cancer

Gastroenterologists work with patients to determine appropriate surveillance and risk management.
Our specialists follow recommendations from the National Comprehensive Cancer Network (NCCN), including:
- Colonoscopy starting at age 25-30
- Repeat colonoscopy every one to three years depending on the number of polyps found

Risks to Family Members

P/LP variants in the AXIN2 gene are inherited in an autosomal dominant fashion. This means that children, brothers, sisters, and parents of individuals with an AXIN2 P/LP variant have a 1 in 2 (or 50%) chance of having the P/LP variant as well. Both males and females can inherit a familial AXIN2 P/LP variant, and both males and females can pass it on to their children.

BAP1-Associated Cancers

What You Should Know About BAP1 Pathogenic/Likely Pathogenic Variants

Individuals with a pathogenic/likely pathogenic (P/LP) variant in the BAP1 gene have an increased risk for developing cancers of the kidney, skin, eyes, and lungs over their lifetime.

With one of the largest hereditary cancer programs in the country, UT Southwestern offers tailored care for individuals with BAP1 P/LP variants.

Cancer Risks Associated with a BAP1 Mutation

Approximately 10% of individuals with a BAP1 P/LP variant have kidney cancer. Individuals with the variant also have an increased risk for developing melanoma of the skin (cutaneous) or eyes (uveal) and may develop another skin finding called a BAP1-inactivated melanocytic tumor (BIMT), which has a low risk of turning into cancer. A form of lung cancer called malignant mesothelioma has also been observed in individuals with a BAP1 P/LP variant.

Managing Cancer Risks

UT Southwestern’s Genetic Cancer Prevention Clinic (GCPC) can help ensure people are receiving appropriate cancer surveillance and management based on their genetic testing results. For more information about the GCPC or to request an appointment, please call us at 214-645-2563.

Skin Cancers

Dermatologists at UT Southwestern work with patients to determine an appropriate skin cancer surveillance plan.
- This plan often includes a full-body skin exam.

Uveal Melanoma

Ophthalmologists at UT Southwestern work with patients to establish a surveillance plan for uveal melanoma.
This surveillance often includes a dilated eye exam and baseline imaging.

Kidney Cancer

Urology specialists work with patients to determine appropriate surveillance and risk management for hereditary kidney cancer.
Our specialists follow established surveillance guidelines, including:
- Abdominal MRI or CT every two years

Risks to family Members

P/LP variants in the BAP1 gene are inherited in an autosomal dominant fashion. This means that parents, brothers, sisters, and children of individuals with a BAP1 P/LP variant have a 1 in 2 or 50% chance of having the same variant.

BARD1-Associated Cancers

What You Should Know About BARD1 Pathogenic/Likely Pathogenic Variants

Females with a BARD1 pathogenic/likely pathogenic (P/LP) variant have increased risks for developing cancers of the breast.

UT Southwestern is home to one of the nation’s largest hereditary cancer programs, and we provide expert care for patients with P/LP BARD1 variants.

Cancer Risks Associated with a BARD1 Mutation

Females with a P/LP variant in the BARD1 gene have up to a 30% risk of developing breast cancer over their lifetime.

Managing Cancer Risks

UT Southwestern’s Genetic Cancer Prevention Clinic (GCPC) can help ensure people are receiving appropriate cancer surveillance and management based on their genetic testing results. For more information about the GCPC or to request an appointment, please call us at 214-645-2563.

Breast Cancer

Breast specialists at UT Southwestern work with patients to determine individual screening and surgical management.
Our specialists follow recommendations from the National Comprehensive Cancer Network (NCCN), including:
- Annual mammogram and breast MRI

Risks to family Members

P/LP variants in the BARD1 gene are inherited in an autosomal dominant fashion. This means that parents, brothers, sisters, and children of individuals with a BARD1 P/LP variant have a 1 in 2 or 50% chance of having the same variant.

Birt Hogg Dubé Syndrome (FLCN mutations)

What You Should Know About FLCN Pathogenic/Likely Pathogenic Variants

Individuals with a pathogenic/likely pathogenic (P/LP) variant in the FLCN gene have Birt-Hogg-Dube syndrome (BHD), which increases the risk for skin lesions, lung cysts, and pneumothorax (collapsed lung). Individuals also have an increased risk for kidney cancer.

UTSW is recognized as a VHL Alliance Clinical Care Center (CCC). This designation emphasizes our commitment to providing outstanding, coordinated care for individuals with hereditary kidney cancer syndromes, including BHD.

Cancer Risks Associated with an FLCN P/LP Variant

Individuals with an FLCN P/LP variant have an increased risk for tumors of the kidney, including kidney cancer; 20-35% of people with the variant develop a kidney tumor. These tumors can be benign or cancerous.

Managing Cancer Risks

UT Southwestern’s Genetic Cancer Prevention Clinic (GCPC) can help ensure people are receiving appropriate cancer surveillance and management based on their genetic testing results. For more information about the GCPC or to request an appointment, please call us at 214-645-2563.

Kidney Cancer

Our kidney specialists work with patients to determine appropriate surveillance and risk management.
Our specialists follow recommendations from the National Comprehensive Cancer Network (NCCN), including:
- Abdominal/pelvic CT scan with contrast, MRI, or renal ultrasound starting at age 20
- Repeat every one to three years based on findings

Other Features

Specialists in dermatology, pulmonology, and other disciplines may also be an important part of the care team.
Additional surveillance or management recommendations might include:
- Full skin exam
- High-resolution computer tomography (HRCT) or CT of the chest
Lifestyle modifications should be considered, including avoiding cigarette smoking, high altitudes, and high ambient pressure.

Risks to Family Members

P/LP variants in the FLCN gene are inherited in an autosomal dominant fashion. This means that children, brothers, sisters, and parents of individuals with an FLCN P/LP variant have a 1 in 2 (or 50%) chance of having the P/LP variant as well. Both males and females can inherit a familial FLCN P/LP variant, and both males and females can pass it on to their children.

BRIP1-Associated Cancers

What You Should Know About BRIP1 Pathogenic/Likely Pathogenic Variants

Individuals with a pathogenic/likely pathogenic (P/LP) variant in the BRIP1 gene are at an increased risk for cancers of the ovary.

Patients with BRIP1 P/LP variants receive specialized care at UTSouthwestern, which hosts one of the largest hereditary cancer programs in the nation.

Cancer Risks Associated with a BRIP1 Mutation

Individuals with a P/LP variant in the BRIP1 gene have up to a 15% chance of developing ovarian cancer in their lifetime. There is a potential increased risk for women with the variant to develop breast cancer, but data are conflicting. Rarely, individuals inherit two P/LP BRIP1 mutations and may develop a condition called Fanconi anemia, increasing the risk for other cancers and developmental differences.

Managing Cancer Risks

UT Southwestern’s Genetic Cancer Prevention Clinic (GCPC) can help ensure people are receiving appropriate cancer surveillance and management based on their genetic testing results. For more information about the GCPC or to request an appointment, please call us at 214-645-2563.

Ovarian Cancer

Gynecologic oncologists work with patients to determine a screening and management plan.
Our specialists follow guidelines from the National Comprehensive Cancer Network(NCCN), including:
- Consideration of surgery to remove the ovaries and fallopian tubes

Risks to family Members

P/LP variants in the BRIP1 gene are inherited in an autosomal dominant fashion. This means that parents, brothers, sisters, and children of individuals with a BRIP1 P/LP variant have a 1 in 2 or 50% chance of having the same variant. Both males and females can have and pass down P/LP variants in the BRIP1 gene. If two individuals have a BRIP1 P/LP variant, there is a 1 in 2 or 50% chance their child will have one variant and 1 in 4 or 25% chance their child will have both variants, consistent with a diagnosis of Fanconi anemia.

CDC73-Associated Cancers

Gene

CDC73

Related Conditions

Familial isolated hyperparathyroidism (FIHP), parathyroid carcinoma, and hyperparathyroidism-jaw tumor (HPT-JT) syndrome

Download Clinical Guide

CDC73 Clinical Guide

CHEK2-Associated Cancers

Individuals with a pathogenic/likely pathogenic (P/LP) variant in the CHEK2 gene have an increased risk for cancers of the breast and prostate. Our knowledge of CHEK2 and the related cancer risk primarily comes from data on one specific pathogenic variant seen predominantly in individuals with Northern European ancestry (this variant is called c.1100del).

Constitutional Mismatch Repair Deficiency (MLH1, MSH2, MSH6, PMS2, EPCAM biallelic mutations)

Gene

MLH1/MSH2/MSH6/PMS2/EPCAM (biallelic mutations or two mutations in the same gene)

Component Cancers

Colon, stomach, small intestine, leukemia, lymphoma, and brain tumors

Other Features

Café au lait spots

Download Fact Sheets

CMMRD Fact Sheet - English

CMMRD Fact Sheet - Spanish

Download Clinical Guides

MLH1 Clinical Guide

MSH2 Clinical Guide

MSH6 Clinical Guide

PMS2 Clinical Guide

EPCAM Clinical Guide

Cowden Syndrome (PTEN mutations)

Individuals with a pathogenic/likely pathogenic (P/LP) variant in the PTEN gene have PTEN hamartoma tumor syndrome (PHTS), which is a spectrum of several conditions that have overlapping features. PHTS can cause noncancerous, tumor-like growths called hamartomas throughout the body.

DICER1-Associated Cancers

Gene

DICER1

Component Cancers/Tumors

Pleuropulmonary blastoma (PPB), cystic nephroma (CN), ovarian Sertoli-Leydig cell tumors (SLCT)

Download Fact Sheet

DICER1 Fact Sheet - English

DICER1 Fact Sheet - Spanish

Download Clinical Guide

DICER1 Clinical Guide

Familial Adenomatous Polyposis (APC mutations)

Familial Adenomatous Polyposis (FAP) is a very rare condition that accounts for about 1% of new cases of colorectal cancer. At UT Southwestern, we have one of the largest hereditary cancer programs in the country and are experienced in working with individuals who have FAP.

Familial Atypical Mole and Malignant Melanoma (CDKN2A mutations)

Individuals with a pathogenic/likely pathogenic (P/LP) variant in the CDKN2A gene have up to an 80% lifetime risk for melanoma, with risks varying based on geographic location. Individuals also have a greater than 15% lifetime risk for pancreatic cancer.

Fanconia Anemia (FA)

Gene

One of 16 genes

Component Cancers/Tumors

Cancers of the blood, head and neck, skin, gastrointestinal (GI), and gynecologic system

Other Features

Increased risks of bone marrow failure (aplastic anemia), physical abnormalities

Download Fact Sheet

FA Fact Sheet - English

FA Fact Sheet - Spanish

Gorlin Syndrome/Nevoid Basal Cell Carcinoma Syndrome (PTCH1 and SUFU mutations)

Genew

PTCH, SUFU

Component Cancers/Tumors

Basal cell carcinomas (BCC), meningiomas, primitive neuroectodermal tumor (PNET), jaw keratocysts, sebaceous and dermoid cysts, cardiac fibromas, fetal rhabdomyomas, ovarian fibromas

Cancer/Tumor Associations with Limited Evidence

Ovarian fibrosarcomas

Other Features

Ectopic calcification of the falx cerebri, palmar/plantar pits, congenital skeletal anomalies, larger head circumference (greater than 97th percentile), cleft lip and/or palate, polydactyly (extra digits), eye anomalies (cataracts, coloboma, microphthalmia)

Download Fact Sheet

PTCH1 Fact Sheet - English

PTCH1 Fact Sheet - Spanish

SUFU Fact Sheet - English

SUFU Fact Sheet - Spanish

Download Clinical Guide

PTCH1 Clinical Guide

SUFU Clinical Guide

GREM1-Associated Cancers

Gene

GREM1

Component Cancers/Tumors

Colorectal cancer and polyps

Download Fact Sheet

GREM1 Fact Sheet - English

GREM1 Fact Sheet - Spanish

Hereditary Breast and Ovarian Cancer Syndrome (BRCA1 and BRCA2 mutations)

Approximately 5-10% of breast cancer is inherited. Most hereditary breast cancers are caused by pathogenic/likely pathogenic (P/LP) variants in the BRCA1 and BRCA2 genes, but there are other genes that can cause inherited breast cancers.

Hereditary Diffuse Gastric Cancer (CDH1 mutations)

Individuals with a pathogenic/likely pathogenic (P/LP) variant in the CDH1 gene have an increased risk for a specific type of stomach cancer called diffuse or signet ring carcinoma. The lifetime risk for females with the variant to get this cancer is up to 35%, and for males with the variant it is up to 45%. Females with the variant also have up to a 55% lifetime risk for breast cancer.

Hereditary Leiomyomatosis and Renal Cell Cancer (FH mutations)

Gene

FH

Component Cancers/Tumors

Renal cell carcinoma (type II papillary), uterine leiomyosarcoma, uterine and cutaneous leiomyomata

Cancer/Tumor Associations with Limited Evidence

Testicular Leydig cell tumors, adrenal adenomas, ovarian cystadenomas

Download Fact Sheet

FH Fact Sheet - English

FH Fact Sheet - Spanish

Download Clinical Guide

RB1 Fact Sheet - Spanish

Download Clinical Guide

RB1 Clinical Guide

HOXB13-Associated Cancers

Gene

HOXB13

Component Cancers/Tumors

Prostate cancer

Download Clinical Guide

HOXB13 Clinical Guide

Juvenile Polyposis Syndrome (BMPR1A and SMAD4 mutations)

Gene

BMPR1A/SMAD4

Component Cancers/Tumors

GI juvenile-type hamartomatous polyps (stomach, small intestine, colon, and rectum); colon, stomach, upper GI, and pancreatic cancers

Download Fact Sheet

Juvenile Polyposis Syndrome Fact Sheet - English

Juvenile Polyposis Syndrome Fact Sheet - Spanish

Download Clinical Guide

Juvenile Polyposis Clinical Guide

KIT-Associated Cancers

What You Should Know About KIT Pathogenic/Likely Pathogenic Variants

Some pathogenic/likely pathogenic (P/LP) variants in the KIT gene are associated with piebaldism, while other P/LP variants in the KIT gene are associated with gastrointestinal stromal tumors (GISTs) and familial mastocytosis. Piebaldism is associated with lighter than normal patches of hair and skin that are present at birth. GISTs are tumors in the gastrointestinal tract that can be cancerous (malignant) or noncancerous (benign). Mastocytosis is a blood disorder that occurs when white blood cells called mast cells build up in tissue, causing an increased immune response.

With one of the largest hereditary cancer programs in the country, UTSW has significant experience in managing individuals with KIT gene P/LP variants.

Cancer Risks Associated with a KIT P/LP Variant

Individuals with a KIT P/LP variant may have an increased risk for developing GISTs, but the exact risk is unknown. As we continue to learn more about the KIT gene and its associated cancer risks, we may learn there are increased risks for other types of cancers.

Managing Cancer Risks

UT Southwestern’s Genetic Cancer Prevention Clinic (GCPC) can help ensure people receive appropriate cancer surveillance and management based on their genetic testing results. For more information about the GCPC or to request an appointment, please call us at 214-645-2563.

The UTSW GCPC team can review your genetic testing, as well as your personal and family history of cancer, to determine your cancer screening recommendations. The team may suggest earlier screenings or specialized screenings.

Examples of potential cancer screenings include:

Colonoscopies
Upper endoscopies
Abdominal imaging including CT scan or MRI

Risks to Family Members

P/LP variants in the KIT gene are inherited in an autosomal dominant fashion. This means that children, brothers, sisters, and parents of individuals with a KIT P/LP variant have a 1 in 2 (or 50%) chance of having the P/LP variant as well. Both males and females can inherit a familial KIT P/LP variant, and both males and females can pass it on to their children.

Li-Fraumeni Syndrome (TP53 mutations)

Li-Fraumeni syndrome is caused by pathogenic/likely pathogenic (P/LP) variants in the TP53 gene. Individuals with a P/LP variant in the TP53 gene have an increased risk for a broad spectrum of cancers. The most common cancer types seen include breast cancer, brain cancer, blood or hematologic cancers, sarcomas, and tumors of the adrenal gland (adrenocortical carcinoma).

Lynch Syndrome (MLH1, MSH2, MSH6, PMS2 and EPCAM mutations)

Lynch syndrome is an inherited cancer risk condition that increases a person’s chances of developing multiple types of cancer. It is caused by mutations, or breaks, of the MLH1, MSH2, MSH6, PMS2, or EPCAM genes, which support the ability of the cells’ DNA (genetic code) to repair itself and protect against cancer.

MC1R-Associated Cancers

What You Should Know About MC1R Pathogenic/Likely Pathogenic Variants

Individuals with a single pathogenic/likely pathogenic (P/LP) variant in the MC1R gene may have an increased risk for skin cancer, particularly melanoma.

Individuals with two P/LP variants in the MC1R gene (one inherited from each parent) may have a chance for red hair and a fairer skin tone.

UTSW is home to one of the nation’s largest hereditary cancer programs, offering extensive expertise in working with individuals carrying MC1R P/LP variants.

Cancer Risks Associated with an MC1R P/LP Variant

The cancer risks for individuals who have an MC1R P/LP variant are still being understood. However, it has been suggested that individuals with one P/LP variant in the MC1R gene may be at an increased risk of developing skin cancer, particularly melanoma, regardless of skin damage or skin tone. Researchers are actively investigating how MC1R P/LP variants, environmental factors, and melanoma risks are interconnected.

Managing Cancer Risks

UT Southwestern’s Genetic Cancer Prevention Clinic (GCPC) can help ensure people are receiving appropriate cancer surveillance and management based on their genetic testing results. For more information about the GCPC or to request an appointment, please call us at 214-645-2563.

There are no consensus recommendations on the frequency and method of cancer surveillance someone with a P/LP variant in the MC1R gene should have. Individuals may consider a formal dermatological evaluation based on the increased chance of developing skin cancer.

Alongside our dermatology colleagues, the UTSW GCPC team can review your genetic testing, as well as your personal and family history of cancer, to help determine your cancer screening recommendations. The team may suggest earlier screenings or specialized screenings.

Risks to Family Members

P/LP variants in the MC1R gene are inherited in an autosomal dominant fashion. This means that children, brothers, sisters, and parents of individuals with one MC1R P/LP variant have a 1 in 2 (or 50%) chance of having the P/LP variant as well. Both males and females can inherit a familial MC1R P/LP variant, and both males and females can pass it on to their children. If both parents have a P/LP variant in MC1R, their children have a 25% chance to have two P/LP variants in MC1R, a 50% chance to have one P/LP variant, and a 25% chance to have none.

MRE11A-Associated Cancers

Gene

MRE11A

Component Cancers/Tumors

None

Cancers/Tumor Associations with Limited Evidence

Breast and ovarian cancers

Download Clinical Guide

MRE11A Clinical Guide

MSH3-Associated Cancers

Gene

MSH3

Component Cancers/Tumors

Adenomatous polyps in the colon and small intestine, as well as colorectal and stomach cancers

Cancers/Tumor Associations with Limited Evidence

Brain tumors

Download Fact Sheet

MSH3 Fact Sheet - English

MSH3 Fact Sheet - Spanish

Download Clinical Guide

MSH3 Clinical Guide

Multiple Endocrine Neoplasia Type 1 (MEN1 mutations)

What You Should Know About MEN1 Pathogenic/Likely Pathogenic Variants

Individuals with a pathogenic/likely pathogenic (P/LP) variant in the MEN1 gene have a condition called multiple endocrine neoplasia, type 1. MEN1 is associated with an increased risk for several types of endocrine tumors, primarily involving the parathyroid, pancreas, and pituitary gland. These tumors can be benign (noncancerous) or malignant (cancerous).

As a leader in hereditary cancer care, UTSW boasts a large program with deep experience in caring for individuals with MEN1 P/LP variants.

Cancer Risks Associated with a MEN1 P/LP Variant

Individuals with a MEN1 P/LP variant have the following risks:

Parathyroid Tumors (can present as primary hyperparathyroidism): nearly 100% by age 50
Pituitary Tumor: up to a 40% lifetime risk
Tumors of the Gastroenteropancreatic (GEP) Tract: up to a 40% lifetime risk
Carcinoid (Bronchial and Thymic Cancer): up to a 10% lifetime risk
Adrenocortical Cancer: up to a 40% lifetime risk

MEN1 can also be associated with non-endocrine tumors, including: skin findings, central nervous system tumors, leiomyomas, thyroid tumors, and breast cancer.

Managing Cancer Risks

UT Southwestern’s Genetic Cancer Prevention Clinic (GCPC) can help ensure people are receiving appropriate cancer surveillance and management based on their genetic testing results. For more information about the GCPC or to request an appointment, please call us at 214-645-2563.

Endocrine Tumors

Endocrinologists work with patients to determine appropriate surveillance and risk management.
Our specialists follow recommendations from the National Comprehensive Cancer Network (NCCN), including:
- Biochemical workup (such as blood work) to check levels of specific hormones, proteins, glucose, and calcium
- Consideration of imaging such as abdominal/pelvis CT or MRI with contrast, serial EUS, pituitary or sella MRI with contrast, chest CT or MRI with contrast

The frequency of blood work and imaging may vary based on results. Additional screenings or starting screening at a younger age might be considered based on personal risk factors and family history.

Risks to Family Members

The majority (90%) of patients with a MEN1 P/LP variant have an affected parent, but 10% have a de novo variant, meaning it was spontaneous and not inherited. De novo variants can be passed on to children. P/LP variants in the MEN1 gene are inherited in an autosomal dominant fashion. This means that children, brothers, sisters, and parents of individuals with a MEN1 P/LP variant have a 1 in 2 (or 50%) chance of having the P/LP variant as well. Both males and females can inherit a familial MEN1 P/LP variant, and both males and females can pass it on to their children.

Multiple Endocrine Neoplasia Type 2 (RET mutations)

What You Should Know About RET Pathogenic/Likely Pathogenic Variants

Individuals with a pathogenic/likely pathogenic (P/LP) variant in the RET gene have multiple endocrine neoplasia type 2 (MEN2), which increases the risk for thyroid cancer, pheochromocytomas, and hyperparathyroidism.

UTSW is home to one of the largest hereditary cancer programs in the country, with specialized expertise in the clinical management of patients carrying P/LP variants of the RET gene.

Cancer Risks Associated with a RET P/LP Variant

Individuals with a RET P/LP variant have an increased risk for a specific type of thyroid cancer called medullary thyroid cancer. Depending on the specific RET variant that someone has, the risk for medullary thyroid cancer is up to 95%. Individuals also have up to a 35% risk for a type of adrenal tumor called pheochromocytoma and up to a 30% risk for hyperparathyroidism.

Managing Cancer Risks

UT Southwestern’s Genetic Cancer Prevention Clinic (GCPC) can help ensure people are receiving appropriate cancer surveillance and management based on their genetic testing results. For more information about the GCPC or to request an appointment, please call us at 214-645-2563.

Thyroid Cancer

Our endocrinologists work with patients to determine appropriate surveillance and risk management.
Our specialists follow recommendations from the American Thyroid Association, including:
- Annual physical exam, neck ultrasound, and blood work
- Consideration of prophylactic thyroidectomy
- Annual measurement of plasma or 24-hour urinary fractionated metanephrines
- Annual biochemical screening of albumin-corrected calcium or ionized serum calcium measurements
The recommended age of surveillance and surgery depends on the specific RET variant but may begin as early as age 3.

Risks to Family Members

P/LP variants in the RET gene are inherited in an autosomal dominant fashion. This means that children, brothers, sisters, and parents of individuals with a RET P/LP variant have a 1 in 2 (or 50%) chance of having the P/LP variant as well. Both males and females can inherit a familial RET P/LP variant, and both males and females can pass it on to their children.

MUTYH-Associated Cancers

Gene

MUTYH

Component Cancers/Tumors

Colon polyps; colorectal, small bowel, and gastric cancers; osteomas (benign bone tumor) of the jaw, benign tumors of hair follicles

Other features

Extra/impacted teeth, congenital retinal pigment epithelial hypertrophy (CHRPE)

Download Fact Sheets

MUTYH Mutations - English

MUTYH Fact Sheet - Spanish

Download Clinical Guides

MUTYH Clinical Guide

MUTYH-Associated Polyposis (MAP) Clinical Guide

NBN-Associated Cancers

Gene

NBN

Component Cancers/Tumors

Breast cancer

Cancer/Tumor Associations with Limited Evidence

Ovarian, prostate, and skin cancers

Download Fact Sheet

NBN Fact Sheet - English

NBN Fact Sheet - Spanish

Download Clinical Guide

NBN Clinical Guide

Neurofibromatosis Type 1 (NF1 mutations)

What You Should Know About NF1 Pathogenic/Likely Pathogenic Variants

Individuals with a pathogenic/likely pathogenic (P/LP) variant in the NF1 gene have neurofibromatosis 1. Features of NF1 include skin findings (café au lait macules, axillary and inguinal freckling, and neurofibromas), Lisch nodules (benign tumors of the eye), and optic gliomas (brain tumors). While most tumors associated with NF1 are benign, individuals with NF1 have an increased risk of various cancers.

At UTSW, we operate one of the largest hereditary cancer programs in the country, with specialized expertise in the clinical management of patients carrying P/LP variants of the NF1 gene.

Cancer Risks Associated with an NF1 Mutation

Almost all (99%) individuals with an NF1 P/LP variant will develop multiple benign neurofibromas of the skin, which are tumors that grow within a nerve. Approximately 30% of people with NF1 will develop plexiform neurofibromas, which happen under the skin, and up to ~15% of individuals will develop malignant peripheral nerve sheath tumors (MPNSTs), which are more aggressive and happen in the protective layers of nerves. Individuals with NF1 have up to a 20% chance of developing an optic glioma, a 5% chance to develop a non-optic glioma, and may have an increased risk for pheochromocytomas, which are tumors of the adrenal glands. There is also up to a 40% risk for breast cancer and a suspected increased risk for gastrointestinal stromal tumors (GISTs) and leukemia/lymphoma.

Managing Cancer Risks

UT Southwestern’s Genetic Cancer Prevention Clinic (GCPC) can help ensure people are receiving appropriate cancer surveillance and management based on their genetic testing results. For more information about the GCPC or to request an appointment, please call us at 214-645-2563.

Neurofibromas

Dermatologists and genetic specialists work with patients to determine appropriate surveillance and risk management.
Our specialists follow recommendations from the National Comprehensive Cancer Network (NCCN), including:
- Annual physical exam
- Imaging, if clinically indicated

Optic Gliomas

Ophthalmologists work with patients to determine appropriate surveillance and risk management for optic gliomas
Recommendations often include:
- Annual ophthalmologic exam until adolescence, as needed in older childhood

Breast Cancer

Breast specialists work with patients to determine appropriate breast cancer surveillance and risk management.
Our specialists follow recommendations from the NCCN, including:
- Annual mammography with consideration of breast MRI with and without contrast starting at age 30

Other Features

Specialists in neurology, oncology, orthopedics, speech/occupational/physical therapy, and other disciplines may also be an important part of your care team.
Additional surveillance or management recommendations might include:
- Blood pressure monitoring, evaluation of musculoskeletal system, and developmental assessments

RAD50 Clinical Guide

RAD51C-Associated Cancers

What You Should Know About RAD51C Pathogenic/Likely Pathogenic Variants

Individuals with a pathogenic/likely pathogenic (P/LP) variant in the RAD51C gene are at an increased risk for cancers of the breast and ovary.

As one of the largest hereditary cancer programs in the country, UT Southwestern offers specialized care for patients with RAD51C P/LP variants.

Cancer Risks Associated with a RAD51C Mutation

Females with a P/LP RAD51C variant have approximately a 20% risk of developing breast cancer and up to a 15% risk of developing ovarian cancer over their lifetime. Individuals who inherit two P/LP RAD51C mutations may develop a condition called Fanconi anemia (FA), increasing the risk for childhood leukemia and other cancers as well as developmental differences.

Managing Cancer Risks

UT Southwestern’s Genetic Cancer Prevention Clinic (GCPC) can help ensure people are receiving appropriate cancer surveillance and management based on their genetic testing results. For more information about the GCPC or to request an appointment, please call us at 214-645-2563.

Breast Cancer

Breast specialists at UT Southwestern work with patients to determine individual screening and surgical management.
Our specialists follow recommendations from the National Comprehensive Cancer Network (NCCN), including:
- Annual mammogram and breast MRI

Ovarian Cancer

Gynecologic oncologists work with patients to determine a surveillance and management plan for hereditary ovarian cancer.
Our specialists follow recommendations from the NCCN, including:
- Surgery to remove the ovaries and fallopian tubes

Surveillance or management may be recommended at an earlier age depending on family history of cancer and personal risk factors.

Risks to family Members

P/LP variants in the RAD51C gene are inherited in an autosomal dominant fashion. This means that parents, brothers, sisters, and children of individuals with a RAD51C P/LP variant have a 1 in 2 or 50% chance of having the same variant. Both males and females can have and pass down P/LP variants in the RAD51C gene. If two individuals have a P/LP RAD51C variant, there is a 1 in 2 or 50% chance their child will have one variant and 1 in 4 or 25% chance their child will have both variants, consistent with a diagnosis of FA.

RAD51D-Associated Cancers

Gene

RAD51D

Component Cancers/Tumors

Ovarian cancer

Cancers/Tumors Associations with Limited Evidence

Breast cancer

Download Fact Sheet

RAD51D Fact Sheet - English

RAD51D Fact Sheet - Spanish

Download Clinical Guide

RAD51D Clinical Guide

Rhabdoid Tumor Predisposition Type 2 (SMARCA4 mutations)

Gene

SMARCA4

Component Cancers/Tumors

Atypical teratoid/rhabdoid tumors (AT/RT); malignant rhabdoid tumors of the kidney; small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)

Download Fact Sheet

SMARCA4 Fact Sheet - English

SMARCA4 Fact Sheet - Spanish

Tuberous Sclerosis (TSC1 and TSC2 mutations)

Gene

TSC1/TSC2

Component Cancers/Tumors

Benign hamartomas in multiple organs (skin, CNS, kidney, liver, lungs, heart), renal cancer

Other features

Hypopigmented macules, facial angiofibromas, subependymal nodules, cortical and subcortical tubers, seizures, development delay/intellectual disability, renal angiomyolipomas, cardiac rhabdomyomas

Download Fact Sheet

Tuberous Sclerosis Fact Sheet - English

Tuberous Sclerosis Fact Sheet - Spanish

Download Clinical Guide

Tuberous Sclerosis Clinical Guide

Von Hippel-Lindau (VHL mutations)

Gene

VHL

Component Cancers/Tumors

CNS/retinal hemangioblastomas, renal cancer, pheochromocytoma, pancreatic/liver cysts and tumors, benign tumors in the ear, cystadenomas of the epididymis (males)

Download Fact Sheet

Von-Hippel Lindau Fact Sheet

VHL Fact Sheet - English

VHL Fact Sheet - Spanish

Download Clinical Guide

VHL Clinical Guide